Presse Release - 50 billionth domestic poultry vaccine
Press Release
Budapest, 23/7/2014
50 billionth domestic poultry vaccine reaches completion
Ceva-Phylaxia produces 95% of the vaccines completed in the Budapest factory for export
As a market leader, the so-called immune complex vaccines against one of the most frequent catching disease that affects chickens are produced in Hungary. On the occasion of celebrating the 50 billionth vaccine, Ceva-Phylaxia Ltd, a vaccine manufacturer and Peter
Szijjarto, Deputy Minister of Foreign Affairs and Trade exhibited a commemorative plaque on
today’s press conference.
The so-called Gumboro disease is taken to be the infection causing the greatest loss of domestic fowl and chickens. Against this virus, Hungarian researchers developed a vaccine proved to be the most effective solution, which is made in the headquarters of Ceva-Phylaxia
Ltd in Budapest for almost 10 years. This summer, the 50 billionth vaccine was produced of an amount, which is exported in 95%.
The Hungarian vaccines are marketed in almost all countries in the world, including China,
Brazil, Mexico and the Republic of South-Africa as the largest markets. According to international statistics, all fourth chicken vaccinated against this infection are inoculated with an immune complex vaccine produced in Hungary and developed in the Hungarian Centre of
Research and Development.
Peter Szijjarto, Deputy Minister of Foreign Affairs and Trade has also taken part in this event and told: "The work of the Hungarian veterinary researchers is word-class".
A Ceva Group is present in 42 countries of the world, employs 3,500 people and is one of the 10 largest veterinary companies. As Thierry Le Flohic, Chief Executive Officer of the Hungarian
Ceva-Phylaxia stressed, the company’s international successes are built largely on the results of the Hungarian factory, owing to which we have become the business group’s strategic centre.
In the past years, we made multiple investments in Hungary to be able to expand production.
To date we have earned a dominant world market position in the field of the vaccines produced at home.” – the CEO added.
